---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Administration"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Administration. Topics: Once nightly at bedtime (company description), Administration in the clinical trials, Atomoxetine label: administration with respect to food, and Oxybutynin label: administration of the extended-release tablet with respect to food. 4 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/administration"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Administration

<a id="heading-2.1.2.10.2"></a>

## 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

### Once nightly at bedtime (company description)

> “Oxnimbi is formulated into a small tablet that is taken once nightly, just prior to bedtime.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “AD109 is intended to be a once-daily oral pill taken at bedtime that is designed to lower the complexity of treating OSA.”

Source: [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.2.10.2-2"></a>

### Administration in the clinical trials

> “Participants take the run-in dose nightly at home and return with the bottle and empty blister pack at V4 for IMP accountability.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

> “Participants were instructed to take the study drug nightly immediately before bedtime for 4 weeks.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-2.1.2.10.2-3"></a>

### Atomoxetine label: administration with respect to food

> “STRATTERA may be taken with or without food. Take STRATTERA capsules whole; do not open the capsules.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.10.2-4"></a>

### Oxybutynin label: administration of the extended-release tablet with respect to food

> “DITROPAN XL® must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed. DITROPAN XL® may be administered with or without food.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
